Tag: TET2
Assessing Methylation-Based Sequencing as a Risk-Stratifying Tool in MDS
Methylation-based sequencing appears to be a viable risk-assessment tool for myelodysplastic syndromes (MDS), according to a study presented at the 2023 American Society of Clinical Oncology Annual Meeting. “MDS risk stratification is key for [making] optimal treatment decisions. DNA methylation is associated with MDS biology due to frequent somatic mutations…
A familial SAMD9 variant present in pediatric myelodysplastic syndrome
Cold Spring Harb Mol Case Stud. 2023 Apr; 9(2): a006256. ,1,2 ,1,2 ,1,2 ,2,3 ,4 and 1,2 Mahvish Q. Rahim 1Pediatric Hematology Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA; 2Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA; April Rahrig 1Pediatric Hematology Oncology,…
Phase 3 Findings Demonstrate Durable Benefit With Imetelstat For Patients With R/R MDS
Imetelstat, a first-in-class telomerase inhibitor, decreased transfusion dependence and increased hemoglobin counts for patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome (MDS) that is relapsed or refractory to erythropoiesis stimulating agents (ESAs), according to findings from the phase 3 IMerge trial (NCT02598661) presented during the 2023 ASCO Annual Meeting.1…
Imetelstat Displays Significant Efficacy in R/R Myelodysplastic Syndrome
Statistically significant and clinically meaningful efficacy has been demonstrated with imetelstat, a first-in-class direct and competitive telomerase inhibitor imetelstat, in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome (MDS) that is relapsed or refractory to erythropoiesis stimulating agents (ESAs).1 Findings come from the phase 3 IMerge trial (NCT02598661), which…
Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS
Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome (MDS) that is relapsed or refractory to erythropoiesis stimulating agents (ESAs),according to findings from the phase 3 IMerge trial (NCT02598661) presented during…
2023-05-25 | NYSE:BMY | Press Release
Results from Phase 3 COMMANDS study, selected for ASCO’s official press program,show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent hemoglobin increase vs. epoetin alfa, including in clinically relevant subgroups Reblozyl demonstrated a durable response, with nearly 2.5 years median transfusion independence, 1 year…
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 | Business
FOSTER CITY, Calif.–(BUSINESS WIRE)–May 11, 2023– Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that five abstracts related to imetelstat, a first-in-class telomerase inhibitor, have been accepted at the European Hematology Association (EHA) Annual Meeting taking place from June 8-11, 2023 in Frankfurt, Germany and virtually. The…
Identification of a genomic DNA sequence that quantitatively modulates KLF1 transcription factor expression in differentiating human hematopoietic cells
Laurenti, E. & Gottgens, B. From haematopoietic stem cells to complex differentiation landscapes. Nature (London) 553, 418–426 (2018). ADS CAS PubMed Google Scholar Miller, I. J. & Bieker, J. J. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Krüppel family…
Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation | Clinical Epigenetics
5-Azacytidine pretreatment resensitizes cisplatin-resistant DLBCL cell lines to cisplatin to varying degrees A platinum-based anti-neoplastic agent is an essential component of salvage regimens for aggressive lymphomas, for example, rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) for relapsed/refractory DLBCL and Hodgkin lymphoma [21]. As a single agent in humans, cisplatin is administered…
Coordination of RNA modifications in the brain and beyond
Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17:487–500. Article CAS PubMed Google Scholar Boccaletto P, Stefaniak F, Ray A, Cappannini A, Mukherjee S, Purta E, et al. MODOMICS: a database of RNA modification pathways. 2021 update. Nucleic Acids Res. 2022;50:D231–D235. Article CAS PubMed Google…
The genome-wide mutational consequences of DNA hypomethylation
Goldberg, A. D., Allis, C. D. & Bernstein, E. Epigenetics: A landscape takes shape. Cell 128, 635–638 (2007). Article PubMed Google Scholar Mohn, F. & Schübeler, D. Genetics and epigenetics: Stability and plasticity during cellular differentiation. Trends Genet. 25, 129–136 (2009). Article PubMed Google Scholar Takahashi, K. et al. Induction…
Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing.
Fairchild, Lauren, Whalen, Jeanne, D’Aco, Katie, Wu, Jincheng, Gustafson, Ben, Su, Fei, Leary, Rebecca, Campbell, Katie and Balbin, Oscar (2023) Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. Science translational medicine, 15 (689). ISSN 1946-6242 Abstract In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP)…
MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
Patient selection and data collection This study retrospectively collected 475 patients diagnosed with de novo DLBCL by two experienced pathologists at the CHCAMS and Suzhou Municipal Hospital from February 6th, 2007 to May 20th, 2022. A total of 132 patients with MYD88 variations were included for analysis. The inclusion criteria…
Reprogramming of human peripheral blood mononuclear cells into induced mesenchymal stromal cells using non-integrating vectors
OCT4 alone was insufficient to reprogram PBMCs into iMSCs directly Previously, we reported that lentivirally expressed OCT4 could directly reprogram human cord blood CD34+ hematopoietic progenitor cells into iMSCs with very high efficiency11. Therefore, we first tried to convert human PBMCs into iMSCs by overexpressing OCT4 alone using a clinically…
Mouse study at USC reveals why leukemic mutation varies
A mechanism linked to a genetic mutation could help identify patients who are at higher risk of developing leukaemia. A new study published in Blood, focuses on a genetic mutation associated with leukaemia. While some individuals with this mutation remain healthy, others develop the disease. The researchers at the USC Stem…
Why does a leukemic mutation not always lead to leukemia? A new clue from a mouse study
Credit: Pixabay/CC0 Public Domain Why do some people with a genetic mutation associated with leukemia remain healthy, while others with the same mutation develop the blood cancer? In a new study published in Blood, scientists from the USC Stem Cell laboratory of Rong Lu discovered a mechanism that linked a…
Reactome | GSN(404-782) [cytosol]
UniProt:P68135 ACTS 0.867 10 UniProt:P07830 4 act9 [extracellular region] (R-DDI-350725-3) act9 [nucleoplasm] (R-DDI-3321990-3) act9 [cytosol] (R-DDI-201861-3) act9 [plasma membrane] (R-DDI-196016-3) 0.683 5 UniProt:P03372 ESR1 8 p-S118-ESR1 [nucleoplasm] (R-HSA-9024210) monoSUMO1-5K-ESR1 [nucleoplasm] (R-HSA-4090302) Me260-PalmS-ESR1 [plasma membrane] (R-HSA-9637788) PalmS-ESR1 [plasma membrane] (R-HSA-9021057) PalmS-ESR1 [cytosol] (R-HSA-9020974) Me260-ESR1 [cytosol] (R-HSA-9632177) ESR1 [nucleoplasm] (R-HSA-446168)…
DLBCL therapeutic strategies and gene-oriented treatment
Background Lymphoma is a group of heterogeneous hematological malignancies, which are classified into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive NHL. DLBCL can be divided into germinal center B-cell-like (GCB) subgroup and non-GCB subgroup according to the origin of cells….
Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes
In general, more than half of MDS patients are diagnosed at age 75 years or older, and the incidence rate of MDS in patients under 50 years of age is as low as less than 1 per 100,000)3. The median number of gene mutations in patients with MDS has been found to…
015274 UCD Post-doctoral Research Fellow Level 1 or Level 2, School of Biomolecular and Biomedical Science, Temporary 30 months post
Applications are invited for a temporary post of a Post-doctoral Research Fellow Level 1 or Level 2 within UCD School of Biomolecular and Biomedical Science. The Chromatin Architecture in Cancer laboratory at University College Dublin, led by Dr. Eric Conway, are recruiting a postdoctoral fellow to work on the role…
Dynamics of DNA hydroxymethylation and methylation during mouse embryonic and germline development
Gu, T. P. et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 477, 606–610 (2011). Article CAS Google Scholar Wossidlo, M. et al. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat. Commun. 2, 241 (2011). Article Google Scholar Iqbal, K., Jin, S….
Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation
Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911–917 (2018). CAS PubMed PubMed Central Google Scholar Yizhak, K. et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science 364, eaaw0726 (2019). CAS PubMed PubMed Central Google Scholar Yokoyama, A….
Impact of DNA mutations on lifelong blood cell production uncovered — ScienceDaily
New research has uncovered how genetic mutations hijack the production of blood cells in different periods of life. Scientists at the Wellcome Sanger Institute, the Cambridge Stem Cell Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI) and collaborators show how these changes relate to ageing and the development of age-related diseases, including…
